Quick Answer
Hepion Pharmaceuticals, Inc. reported R&D Expense of $445.5 thousand for fiscal year 2025.
Hepion Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $445.5K | -96.2% |
| 2024 | $11.85M | -66.8% |
| 2023 | $35.64M | +7.1% |
| 2022 | $33.27M | +63.1% |
| 2021 | $20.40M | +70.0% |
| 2020 | $12.00M | +276.8% |
| 2019 | $3.18M | -58.1% |
| 2018 | $7.59M | -43.2% |
| 2017 | $13.37M | -2.1% |
| 2017 | $13.65M | -9.1% |
| 2016 | $15.02M | +78.7% |
| 2015 | $8.40M | +2574.2% |
| 2014 | $314.2K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $423.3K | -94.1% | +1803.7% |
| March 31, 2025 | $22.2K | -99.1% | -99.2% |
| September 30, 2024 | $2.76M | -67.6% | -61.3% |
| June 30, 2024 | $7.14M | -39.9% | +181.0% |
| March 31, 2024 | $2.54M | -74.1% | -70.2% |
| September 30, 2023 | $8.52M | +48.4% | -28.3% |
| June 30, 2023 | $11.88M | -24.3% | +21.3% |
| March 31, 2023 | $9.80M | +127.3% | +70.7% |
- Hepion Pharmaceuticals, Inc. showed a decrease of -96.2% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Hepion Pharmaceuticals, Inc.’s r&d expense has grown by 41.8% (from $314.2 thousand to $445.5 thousand).
- The most recent figure is from Hepion Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: